O	0	1	A
O	2	7	phase
O	8	11	III
O	12	20	adjuvant
O	21	31	randomised
O	32	37	trial
O	38	40	of
B-intervention	41	42	6
I-intervention	43	49	cycles
I-intervention	50	52	of
I-intervention	53	54	5
I-intervention	54	55	-
I-intervention	55	67	fluorouracil
I-intervention	67	68	-
I-intervention	68	79	epirubicine
I-intervention	79	80	-
I-intervention	80	96	cyclophosphamide
I-intervention	97	98	(
I-intervention	98	104	FEC100
I-intervention	104	105	)
O	106	112	versus
B-control	113	114	4
I-control	115	118	FEC
I-control	119	122	100
I-control	123	131	followed
I-control	132	134	by
I-control	135	136	4
I-control	137	142	Taxol
I-control	143	144	(
I-control	144	147	FEC
I-control	147	148	-
I-control	148	149	T
I-control	149	150	)
O	151	153	in
B-eligibility	154	158	node
I-eligibility	159	167	positive
I-eligibility	168	174	breast
I-eligibility	175	181	cancer
I-eligibility	182	190	patients
O	191	192	(
O	192	197	Trial
O	198	203	B2000
O	203	204	)
O	204	205	.

O	206	214	Standard
O	215	223	adjuvant
O	224	236	chemotherapy
O	237	245	regimens
O	246	249	for
O	250	258	patients
O	259	263	with
O	264	268	node
O	269	277	positive
O	278	279	(
O	279	280	N
O	280	281	+
O	281	282	)
O	283	289	breast
O	290	296	cancer
O	297	306	consisted
O	307	309	of
O	310	323	anthracycline
O	324	332	followed
O	333	335	by
O	336	342	taxane
O	342	343	.

O	344	347	The
O	348	356	European
O	357	368	Association
O	369	372	for
O	373	381	Research
O	382	384	in
O	385	393	Oncology
O	394	402	embarked
O	403	405	in
O	406	410	2000
O	411	413	on
O	414	415	a
O	416	421	phase
O	422	425	III
O	426	431	trial
O	432	441	comparing
O	442	443	6
O	444	450	cycles
O	451	453	of
O	454	460	FEC100
O	461	467	versus
O	468	469	4
O	470	476	FEC100
O	477	485	followed
O	486	488	by
O	489	490	4
O	491	496	Taxol
O	496	497	.

O	498	505	Primary
O	506	509	end
O	509	510	-
O	510	515	point
O	516	519	was
B-outcome-Measure	520	527	disease
I-outcome-Measure	528	532	free
I-outcome-Measure	533	541	survival
O	541	542	.

O	543	552	Secondary
O	553	556	end
O	556	557	-
O	557	563	points
O	564	568	were
B-outcome-Measure	569	576	overall
I-outcome-Measure	577	585	survival
O	585	586	,
B-outcome-Measure	587	592	local
I-outcome-Measure	593	603	recurrence
I-outcome-Measure	604	608	free
I-outcome-Measure	609	617	interval
O	617	618	,
B-outcome-Measure	619	629	metastases
I-outcome-Measure	630	634	free
I-outcome-Measure	635	643	interval
O	644	647	and
B-outcome-Measure	648	654	safety
O	654	655	.

O	656	663	Between
O	664	669	March
O	670	674	2000
O	675	678	and
O	679	687	December
O	688	692	2002
O	692	693	,
B-total-participants	694	697	837
O	698	706	patients
O	707	711	were
O	712	722	randomised
O	723	730	between
O	731	738	6FEC100
O	739	742	for
O	743	744	6
O	745	751	cycles
O	752	753	(
B-intervention-participants	753	756	417
O	757	765	patients
O	765	766	)
O	767	769	or
O	770	776	FEC100
O	777	780	for
O	781	782	4
O	783	789	cycles
O	790	794	then
O	795	800	Taxol
O	801	806	175mg
O	806	807	/
O	807	808	m
O	808	809	(
O	809	810	2
O	810	811	)
O	811	812	/
O	812	813	3
O	814	819	weeks
O	820	823	for
O	824	825	4
O	826	832	cycles
O	833	834	(
O	834	841	4FEC100
O	841	842	-
O	842	844	4T
O	844	845	)
O	846	847	(
B-control-participants	847	850	420
O	851	859	patients
O	859	860	)
O	860	861	.

B-total-participants	862	865	One
I-total-participants	866	874	thousand
O	875	883	patients
O	884	887	had
O	888	892	been
O	893	900	planned
O	901	910	initially
O	911	914	but
O	915	918	the
O	919	924	trial
O	925	928	was
O	929	935	closed
O	936	943	earlier
O	944	947	due
O	948	950	to
O	951	955	slow
O	956	963	accrual
O	963	964	.

O	965	971	Hazard
O	972	978	ratios
O	979	980	(
O	980	983	HRs
O	983	984	)
O	985	989	were
O	990	991	0
O	991	992	.
O	992	994	99
O	995	998	for
B-outcome	999	1006	disease
I-outcome	1006	1007	-
I-outcome	1007	1011	free
I-outcome	1012	1020	survival
I-outcome	1021	1022	(
I-outcome	1022	1025	DFS
I-outcome	1025	1026	)
O	1027	1028	(
O	1028	1030	95
O	1030	1031	%
O	1031	1033	CI
O	1033	1034	:
O	1035	1036	0
O	1036	1037	.
O	1037	1039	77
O	1039	1040	-
O	1040	1041	1
O	1041	1042	.
O	1042	1044	26
O	1044	1045	;
O	1046	1047	p
O	1047	1048	=
O	1048	1049	0
O	1049	1050	.
O	1050	1052	91
O	1052	1053	)
O	1053	1054	,
O	1055	1058	and
O	1059	1060	0
O	1060	1061	.
O	1061	1063	85
O	1064	1067	for
B-outcome	1068	1075	overall
I-outcome	1076	1084	survival
I-outcome	1085	1086	(
I-outcome	1086	1088	OS
I-outcome	1088	1089	)
O	1090	1091	(
O	1091	1093	95
O	1093	1094	%
O	1094	1096	CI
O	1096	1097	:
O	1098	1099	0
O	1099	1100	.
O	1100	1102	62
O	1102	1103	-
O	1103	1104	1
O	1104	1105	.
O	1105	1107	15
O	1107	1108	;
O	1109	1110	p
O	1110	1111	=
O	1111	1112	0
O	1112	1113	.
O	1113	1115	29
O	1115	1116	)
O	1116	1117	.

B-outcome	1118	1122	Nine
I-outcome	1122	1123	-
I-outcome	1123	1127	year
I-outcome	1128	1131	DFS
O	1132	1136	were
B-iv-bin-percent	1137	1139	62
I-iv-bin-percent	1139	1140	.
I-iv-bin-percent	1140	1141	9
I-iv-bin-percent	1141	1142	%
O	1143	1149	versus
B-cv-bin-percent	1150	1152	62
I-cv-bin-percent	1152	1153	.
I-cv-bin-percent	1153	1154	5
I-cv-bin-percent	1154	1155	%
O	1156	1159	for
O	1160	1167	6FEC100
O	1168	1171	and
O	1172	1179	4FEC100
O	1179	1180	-
O	1180	1182	4T
O	1182	1183	,
O	1184	1196	respectively
O	1196	1197	.

B-outcome	1198	1202	Nine
I-outcome	1202	1203	-
I-outcome	1203	1207	year
I-outcome	1208	1210	OS
O	1211	1215	were
B-iv-bin-percent	1216	1218	73
I-iv-bin-percent	1218	1219	.
I-iv-bin-percent	1219	1220	9
I-iv-bin-percent	1220	1221	%
O	1222	1228	versus
B-cv-bin-percent	1229	1231	77
I-cv-bin-percent	1231	1232	%
O	1233	1236	for
O	1237	1244	6FEC100
O	1245	1248	and
O	1249	1256	4FEC100
O	1256	1257	-
O	1257	1259	4T
O	1259	1260	,
O	1261	1273	respectively
O	1273	1274	.

O	1275	1283	Toxicity
O	1284	1292	analyses
O	1293	1298	based
O	1299	1301	on
O	1302	1305	803
O	1306	1315	evaluable
O	1316	1324	patients
O	1325	1331	showed
O	1332	1336	that
O	1337	1344	overall
B-outcome	1345	1350	grade
I-outcome	1351	1352	3
I-outcome	1352	1353	-
I-outcome	1353	1354	4
I-outcome	1355	1365	toxicities
O	1366	1370	were
O	1371	1378	similar
O	1379	1381	in
O	1382	1386	both
O	1387	1391	arms
O	1392	1393	(
B-iv-bin-percent	1393	1395	63
I-iv-bin-percent	1395	1396	%
O	1397	1403	versus
B-cv-bin-percent	1404	1406	58
I-cv-bin-percent	1406	1407	%
O	1408	1411	for
O	1412	1419	6FEC100
O	1420	1423	arm
O	1424	1427	and
O	1428	1435	4FEC100
O	1435	1436	-
O	1436	1438	4T
O	1439	1442	arm
O	1442	1443	,
O	1444	1456	respectively
O	1456	1457	;
O	1458	1459	p
O	1459	1460	=
O	1460	1461	0
O	1461	1462	.
O	1462	1464	16
O	1464	1465	)
O	1465	1466	.

O	1467	1469	In
O	1470	1474	this
O	1475	1480	trial
O	1481	1490	replacing
O	1491	1494	the
O	1495	1499	last
O	1500	1501	2
O	1502	1508	FEC100
O	1509	1515	cycles
O	1516	1518	of
O	1519	1526	6FEC100
O	1527	1534	regimen
O	1535	1537	by
O	1538	1539	4
O	1540	1545	Taxol
O	1546	1550	does
O	1551	1554	not
O	1555	1559	lead
O	1560	1562	to
O	1563	1564	a
O	1565	1576	discernable
O	1577	1580	DFS
O	1581	1583	or
O	1584	1586	OS
O	1587	1596	advantage
O	1596	1597	.

O	1598	1601	The
O	1602	1606	lack
O	1607	1609	of
O	1610	1611	a
O	1612	1623	significant
O	1624	1634	difference
O	1635	1642	between
O	1643	1646	the
O	1647	1657	randomised
O	1658	1667	treatment
O	1668	1672	arms
O	1673	1676	may
O	1677	1684	however
O	1685	1687	be
O	1688	1691	due
O	1692	1694	to
O	1695	1696	a
O	1697	1701	lack
O	1702	1704	of
O	1705	1710	power
O	1711	1713	of
O	1714	1718	this
O	1719	1724	trial
O	1725	1727	to
O	1728	1734	detect
O	1735	1740	small
O	1740	1741	,
O	1742	1745	yet
O	1746	1756	clinically
O	1757	1767	worthwhile
O	1767	1768	,
O	1769	1778	treatment
O	1779	1787	benefits
O	1787	1788	.
